Behandling med Lansoprazol- CT® 30 mg leder derfor til en let øget risiko for infektioner i mave- tarmkanalen, såsom med salmonella og Campylobacter.
Treatment with Lansoprazol-CT therefore leads to a slightly increased risk of infections in the gastrointestinal tract, such as with salmonella and Campylobacter.